

2010

LumiMotion

2011

**Digital** 

**Pathology** 

2011

**iCT** 

Scan

# Philips Research Europe 100 years of delivering meaningful innovations



2011

**Airfloss** 

2011

**FreeStreet** 

2012

Hue

2012

**BlueTouch** 

**Pain Relief** 


2013

**AlluraClarity** 

# Philips: A strong diversified industrial group leading in health and well-being



# A strong diversified industrial group leading in health and well-being




# We're getting older and sicker

By 2050, 50% of the developed world is projected to be chronically ill



# The rate of change is accelerating

Innovation introduces both complexity and promise



# Demand for care is growing

There are simply not enough (qualified) nurses and doctors to cope with our growing (and aging) population. Rising healthcare costs are unsustainable.



# Aspirational innovation goals derived from grand societal challenges











Obesity

Access to care

Cancer

Cardiovascular Ageing society


Grand societal challenges: Where can we make a difference?













Our aspirations: Where do we want to win through meaningful innovations?

# Transforming care – today and tomorrow

#### Today



**Imaging**Early and confident diagnosis



Clinical IT
Right information at the right time



**Lifecycle services**Optimising your equipment and training your staff



Home Healthcare
Improving the quality of life for at-risk patients in the home

#### Tomorrow



Image guided intervention and open source approach Advanced visualisation while helping minimize patient side effects.



Clinical Decision Support

Tools based on an understanding of disease pathways and user insights




Partnership solutions
Customised services and healing
environments for improved efficiency,
staff performance, and patient care



Care everywhere
Monitoring and management,
wherever a patient goes

# Challenge: Rapid rise of cardiovascular diseases

Today, 30% of all global deaths are caused by CVD By 2030, about 24 million people will die from CVD Estimated annual cost of CVD 310 B€ (US), 169 B€ (EU), 31 B€ (China)



# Our solution:


# First time right minimally-invasive cardiac procedures

IGIT solutions for cardiology procedures enabling safe, cost-effective cure



#### **Interventional Imaging**


- Ultra low dose 3D X-Ray imaging
- Sharp images through noise reduction algorithms
- 3D real time Ultrasound Imaging



#### **Workflow integration**

Real-time visualization and guidance for catheters

- Heart navigator for valve replacement
- EP navigator for ablate treatment of atrial fibrillation
- EchoNavigator for mitral valve repair



#### In-body sensing and imaging

- Cardiac ablation depth monitoring for EP via ultrasound transducers integrated on catheter tip
- Real time 3D shape sensing with optical fibers

# Clinical Need



First time success rate




1-2%
Patients treated with catheter ablation




Additional costs due to Atrial Fibrillation patients

\$26 Bn


# **Device Miniaturization**



- Miniaturized Ultrasound Transducers
- Catheter prototypes built with four individual transducers to image cardiac tissue in any orientation








# Ultrasound Imaging Expertise

Image processing enabling the physician to see treatment efficacy with the blink of an eye



# Challenge: rapid rise of cancer

Cancer is a leading cause of death worldwide
By 2030, about 13.1 million people per year are estimated to die from cancer. Economic toll for cancer is still increasing (\$895 billion in 2008 excluding direct medical costs)

(source: WHO)





# **Image-guided intervention & therapy**





SEE

**Imaging** 

Procedure planning
Image guidance of treatment



Catheters, needles Navigation/robotics



Therapeutic devices and systems


# Our Aspiration: IGIT solutions for precise cancer diagnosis and treatment

## Providing better outcomes with radically reduced side effects



#### **Diagnostics and Prognostics**

- Improved imaging systems to enable clinicians to better read and interpret images and make an initial diagnosis
- Integration with other sources of information, e.g. pathology



#### Therapy planning

- Image segmentation and multimodal technologies to provide contextual information
- Imaging to guide interventional therapy, minimizing collateral damage
- Radiotherapy planning: dose painting



#### **Image-guided treatment**

- Image-guided interventional and focal therapies
- •MR-Radiotherapy, eg MR-LINAC
- MR-HIFU

# MR guided High Intensity Focused Ultrasound

- 1. Non-invasive thermal tumor therapy
- 2. MR guided: treatment planning based on 3D MR images
- 3. Focused Ultrasound heats tissue noninvasively through intact skin
- 4. MR controlled treatment: real time temperature imaging



Philips Sonalleve MR HIFU system

# Sonalleve creates value for the patient

Uterine fibroids, a benign tumor affecting 70-80% of women by age 50\*

Non-invasive low pain alternative to surgery

Out-patient procedure
Go home the same day

Quick recovery: Return to normal activity in 2 days

Uterus preserving therapy
Future pregnancy promising



\*Source: AHRQ Publication No. 07-E011: Management of Uterine Fibroids: An Update of the Evidence.

# At Philips we strive to make the world healthier and more sustainable through innovation



